Treatment of hemorrhagic purpura includes aggressive anti-infective therapy, correction of coagulation abnormalities, and surgical removal of necrotic skin tissue.
Hemorrhagic purpura is a rapidly progressing and acute disease, often without platelet count reduction. Patients with hemorrhagic purpura often present with sudden onset of flaky symmetrical ecchymosis with tenderness.
1. At present, the specific pathogenesis of this disease is not very clear, but most of the patients are related to infections, such as bacterial, viral infections, etc., so it is necessary to actively anti-inflammatory or anti-viral treatment, including levofloxacin and other drugs.
2. Patients with this disease may have severe coagulation dysfunction, often accompanied by protein C and protein S deficiency, and diffuse intravascular coagulation may occur in severe cases, so it is necessary to dynamically monitor coagulation changes and actively correct coagulation abnormality in order to reduce bleeding, such as plasma transfusion and so on.
3. Skin necrosis may easily occur in the ecchymosis area of the patient’s skin, and timely surgical excision of necrotic tissues is needed, otherwise the necrotic tissues may become infected and further aggravate the primary condition.
It is recommended that the patient should consult a doctor in time, and according to the specific condition, formulate a treatment plan under the guidance of the doctor and actively treat.